25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Ardelyx Inc
Buy, Hold or Sell?

Let's analyze Ardelyx together

I guess you are interested in Ardelyx Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ardelyx Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Ardelyx Inc

I send you an email if I find something interesting about Ardelyx Inc.

1. Quick Overview

1.1. Quick analysis of Ardelyx (30 sec.)










1.2. What can you expect buying and holding a share of Ardelyx? (30 sec.)

How much money do you get?

How much money do you get?
$0.11
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$0.67
Expected worth in 1 year
$0.53
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.03
Return On Investment
-0.6%

For what price can you sell your share?

Current Price per Share
$5.27
Expected price per share
$4.23 - $7.595
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Ardelyx (5 min.)




Live pricePrice per Share (EOD)
$5.27
Intrinsic Value Per Share
$-2.34 - $5.31
Total Value Per Share
$-1.68 - $5.98

2.2. Growth of Ardelyx (5 min.)




Is Ardelyx growing?

Current yearPrevious yearGrowGrow %
How rich?$158.2m$134.5m$21.2m13.6%

How much money is Ardelyx making?

Current yearPrevious yearGrowGrow %
Making money-$18.1m-$6.6m-$11.5m-63.4%
Net Profit Margin-41.2%-69.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Ardelyx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#284 / 945

Most Revenue
#113 / 945

Most Profit
#655 / 945

Most Efficient
#378 / 945
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Ardelyx?

Welcome investor! Ardelyx's management wants to use your money to grow the business. In return you get a share of Ardelyx.

First you should know what it really means to hold a share of Ardelyx. And how you can make/lose money.

Speculation

The Price per Share of Ardelyx is $5.27. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ardelyx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ardelyx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.67. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ardelyx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-0.1%-0.08-1.5%-0.03-0.5%-0.09-1.8%-0.09-1.7%
Usd Book Value Change Per Share0.050.9%-0.03-0.7%0.132.5%0.020.4%0.010.2%
Usd Dividend Per Share0.000.0%0.030.5%0.000.0%0.010.1%0.000.1%
Usd Total Gains Per Share0.050.9%-0.01-0.1%0.132.5%0.030.5%0.010.2%
Usd Price Per Share6.89-6.95-3.78-4.71-6.91-
Price to Earnings Ratio-504.30--140.00-7.48--32.32--34.89-
Price-to-Total Gains Ratio144.33-134.70--69.44-7.68--91.90-
Price to Book Ratio10.31-10.63-6.87-8.27-14.02-
Price-to-Total Gains Ratio144.33-134.70--69.44-7.68--91.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.27
Number of shares189
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.01
Usd Book Value Change Per Share-0.030.02
Usd Total Gains Per Share-0.010.03
Gains per Quarter (189 shares)-1.395.39
Gains per Year (189 shares)-5.5721.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
121-26-1641712
241-52-2283534
362-79-28125256
483-105-34177078
5103-131-402187100
6124-157-4625105122
7145-184-5229122144
8165-210-5833139166
9186-236-6437157188
10207-262-7041174210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%4.036.00.010.0%6.041.01.012.5%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%8.012.00.040.0%13.027.00.032.5%16.029.03.033.3%
Dividend per Share1.00.03.025.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.046.04.2%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%9.011.00.045.0%14.026.00.035.0%17.028.03.035.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Ardelyx Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.048-0.035+173%0.131-64%0.023+107%0.010+376%
Book Value Per Share--0.6680.658+2%0.568+18%0.531+26%0.535+25%
Current Ratio--4.0304.415-9%3.222+25%4.815-16%8.113-50%
Debt To Asset Ratio--0.5700.535+6%0.415+37%0.441+29%0.333+71%
Debt To Equity Ratio--1.3241.178+12%0.723+83%0.846+56%0.613+116%
Dividend Per Share---0.027-100%-0%0.005-100%0.003-100%
Enterprise Value--1612760060.0001654865800.000-3%939052485.000+72%1177197332.730+37%1723870093.365-6%
Eps---0.003-0.077+2143%-0.028+721%-0.095+2677%-0.087+2451%
Ev To Ebitda Ratio--79.6981.211+6481%5.651+1310%-5.393+107%-21.071+126%
Ev To Sales Ratio--4.1047.647-46%10.954-63%97.324-96%infnan%
Free Cash Flow Per Share--0.002-0.067+4482%-0.071+4707%-0.098+6467%-0.089+5902%
Free Cash Flow To Equity Per Share--0.0130.021-37%0.076-83%0.016-20%0.007+86%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--5.310--------
Intrinsic Value_10Y_min---2.344--------
Intrinsic Value_1Y_max---0.228--------
Intrinsic Value_1Y_min---0.341--------
Intrinsic Value_3Y_max---0.107--------
Intrinsic Value_3Y_min---0.938--------
Intrinsic Value_5Y_max--0.714--------
Intrinsic Value_5Y_min---1.437--------
Market Cap1248220580.000-31%1631924060.0001646135300.000-1%894715985.000+82%1115699582.730+46%1635653918.3650%
Net Profit Margin---0.008-0.412+4901%-0.690+8285%-12.757+154817%-80.150+973197%
Operating Margin--0.046-0.336+831%-0.610+1428%-12.181+26605%-75.945+165346%
Operating Ratio--0.9771.379-29%1.655-41%13.436-93%97.541-99%
Pb Ratio7.885-31%10.30910.628-3%6.871+50%8.271+25%14.019-26%
Pe Ratio-385.729+24%-504.303-140.004-72%7.476-6845%-32.322-94%-34.888-93%
Price Per Share5.270-31%6.8906.950-1%3.778+82%4.710+46%6.9060%
Price To Free Cash Flow Ratio857.294-31%1120.827261.101+329%-4.790+100%44.086+2442%5.680+19631%
Price To Total Gains Ratio110.394-31%144.329134.699+7%-69.435+148%7.678+1780%-91.897+164%
Quick Ratio--5.4836.418-15%4.149+32%6.583-17%10.310-47%
Return On Assets---0.002-0.056+2450%-0.031+1324%-0.117+5202%-0.115+5139%
Return On Equity---0.005-0.116+2177%-0.052+923%-0.218+4171%-0.190+3625%
Total Gains Per Share--0.048-0.007+115%0.131-64%0.029+67%0.013+274%
Usd Book Value--158297000.000155748500.000+2%134518000.000+18%125790100.000+26%126826250.000+25%
Usd Book Value Change Per Share--0.048-0.035+173%0.131-64%0.023+107%0.010+376%
Usd Book Value Per Share--0.6680.658+2%0.568+18%0.531+26%0.535+25%
Usd Dividend Per Share---0.027-100%-0%0.005-100%0.003-100%
Usd Enterprise Value--1612760060.0001654865800.000-3%939052485.000+72%1177197332.730+37%1723870093.365-6%
Usd Eps---0.003-0.077+2143%-0.028+721%-0.095+2677%-0.087+2451%
Usd Free Cash Flow--364000.000-15949500.000+4482%-16767750.000+4707%-23175700.000+6467%-21120850.000+5902%
Usd Free Cash Flow Per Share--0.002-0.067+4482%-0.071+4707%-0.098+6467%-0.089+5902%
Usd Free Cash Flow To Equity Per Share--0.0130.021-37%0.076-83%0.016-20%0.007+86%
Usd Market Cap1248220580.000-31%1631924060.0001646135300.000-1%894715985.000+82%1115699582.730+46%1635653918.3650%
Usd Price Per Share5.270-31%6.8906.950-1%3.778+82%4.710+46%6.9060%
Usd Profit---809000.000-18145750.000+2143%-6642500.000+721%-22516800.000+2683%-20677475.000+2456%
Usd Revenue--98241000.00062962250.000+56%33567750.000+193%20700900.000+375%13356850.000+636%
Usd Total Gains Per Share--0.048-0.007+115%0.131-64%0.029+67%0.013+274%
 EOD+3 -5MRQTTM+24 -15YOY+25 -125Y+27 -1210Y+26 -12

3.3 Fundamental Score

Let's check the fundamental score of Ardelyx Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-385.729
Price to Book Ratio (EOD)Between0-17.885
Net Profit Margin (MRQ)Greater than0-0.008
Operating Margin (MRQ)Greater than00.046
Quick Ratio (MRQ)Greater than15.483
Current Ratio (MRQ)Greater than14.030
Debt to Asset Ratio (MRQ)Less than10.570
Debt to Equity Ratio (MRQ)Less than11.324
Return on Equity (MRQ)Greater than0.15-0.005
Return on Assets (MRQ)Greater than0.05-0.002
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Ardelyx Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.043
Ma 20Greater thanMa 505.192
Ma 50Greater thanMa 1005.714
Ma 100Greater thanMa 2005.813
OpenGreater thanClose5.710
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-12-05 12:46:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Ardelyx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ardelyx to the Biotechnology industry mean.
  • A Net Profit Margin of -0.8% means that $-0.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ardelyx Inc:

  • The MRQ is -0.8%. The company is not making a profit/loss.
  • The TTM is -41.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-0.8%TTM-41.2%+40.4%
TTM-41.2%YOY-69.0%+27.9%
TTM-41.2%5Y-1,275.7%+1,234.5%
5Y-1,275.7%10Y-8,015.0%+6,739.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.8%-109.4%+108.6%
TTM-41.2%-221.4%+180.2%
YOY-69.0%-208.7%+139.7%
5Y-1,275.7%-346.2%-929.5%
10Y-8,015.0%-470.4%-7,544.6%
4.3.1.2. Return on Assets

Shows how efficient Ardelyx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ardelyx to the Biotechnology industry mean.
  • -0.2% Return on Assets means that Ardelyx generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ardelyx Inc:

  • The MRQ is -0.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM-5.6%+5.4%
TTM-5.6%YOY-3.1%-2.5%
TTM-5.6%5Y-11.7%+6.1%
5Y-11.7%10Y-11.5%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.2%-11.6%+11.4%
TTM-5.6%-12.0%+6.4%
YOY-3.1%-11.2%+8.1%
5Y-11.7%-12.6%+0.9%
10Y-11.5%-14.2%+2.7%
4.3.1.3. Return on Equity

Shows how efficient Ardelyx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ardelyx to the Biotechnology industry mean.
  • -0.5% Return on Equity means Ardelyx generated $-0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ardelyx Inc:

  • The MRQ is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-11.6%+11.1%
TTM-11.6%YOY-5.2%-6.4%
TTM-11.6%5Y-21.8%+10.2%
5Y-21.8%10Y-19.0%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.5%-14.5%+14.0%
TTM-11.6%-16.0%+4.4%
YOY-5.2%-14.6%+9.4%
5Y-21.8%-18.6%-3.2%
10Y-19.0%-19.3%+0.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Ardelyx Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Ardelyx is operating .

  • Measures how much profit Ardelyx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ardelyx to the Biotechnology industry mean.
  • An Operating Margin of 4.6% means the company generated $0.05  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ardelyx Inc:

  • The MRQ is 4.6%. The company is operating less efficient.
  • The TTM is -33.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ4.6%TTM-33.6%+38.2%
TTM-33.6%YOY-61.0%+27.4%
TTM-33.6%5Y-1,218.1%+1,184.6%
5Y-1,218.1%10Y-7,594.5%+6,376.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.6%-203.3%+207.9%
TTM-33.6%-316.3%+282.7%
YOY-61.0%-216.5%+155.5%
5Y-1,218.1%-378.6%-839.5%
10Y-7,594.5%-480.3%-7,114.2%
4.3.2.2. Operating Ratio

Measures how efficient Ardelyx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.98 means that the operating costs are $0.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ardelyx Inc:

  • The MRQ is 0.977. The company is less efficient in keeping operating costs low.
  • The TTM is 1.379. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.977TTM1.379-0.401
TTM1.379YOY1.655-0.276
TTM1.3795Y13.436-12.058
5Y13.43610Y97.541-84.104
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9772.284-1.307
TTM1.3793.198-1.819
YOY1.6553.263-1.608
5Y13.4364.651+8.785
10Y97.5416.419+91.122
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Ardelyx Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Ardelyx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.03 means the company has $4.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ardelyx Inc:

  • The MRQ is 4.030. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.415. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.030TTM4.415-0.385
TTM4.415YOY3.222+1.193
TTM4.4155Y4.815-0.400
5Y4.81510Y8.113-3.298
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0303.601+0.429
TTM4.4153.872+0.543
YOY3.2224.655-1.433
5Y4.8155.973-1.158
10Y8.1136.258+1.855
4.4.3.2. Quick Ratio

Measures if Ardelyx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ardelyx to the Biotechnology industry mean.
  • A Quick Ratio of 5.48 means the company can pay off $5.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ardelyx Inc:

  • The MRQ is 5.483. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.418. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.483TTM6.418-0.935
TTM6.418YOY4.149+2.269
TTM6.4185Y6.583-0.165
5Y6.58310Y10.310-3.728
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4833.093+2.390
TTM6.4183.416+3.002
YOY4.1494.393-0.244
5Y6.5835.954+0.629
10Y10.3106.436+3.874
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Ardelyx Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Ardelyx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ardelyx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.57 means that Ardelyx assets are financed with 57.0% credit (debt) and the remaining percentage (100% - 57.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ardelyx Inc:

  • The MRQ is 0.570. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.535. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.570TTM0.535+0.035
TTM0.535YOY0.415+0.120
TTM0.5355Y0.441+0.094
5Y0.44110Y0.333+0.108
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5700.345+0.225
TTM0.5350.346+0.189
YOY0.4150.311+0.104
5Y0.4410.365+0.076
10Y0.3330.382-0.049
4.5.4.2. Debt to Equity Ratio

Measures if Ardelyx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ardelyx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 132.4% means that company has $1.32 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ardelyx Inc:

  • The MRQ is 1.324. The company is able to pay all its debts with equity. +1
  • The TTM is 1.178. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.324TTM1.178+0.145
TTM1.178YOY0.723+0.455
TTM1.1785Y0.846+0.332
5Y0.84610Y0.613+0.233
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3240.393+0.931
TTM1.1780.431+0.747
YOY0.7230.384+0.339
5Y0.8460.452+0.394
10Y0.6130.497+0.116
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ardelyx generates.

  • Above 15 is considered overpriced but always compare Ardelyx to the Biotechnology industry mean.
  • A PE ratio of -504.30 means the investor is paying $-504.30 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ardelyx Inc:

  • The EOD is -385.729. Based on the earnings, the company is expensive. -2
  • The MRQ is -504.303. Based on the earnings, the company is expensive. -2
  • The TTM is -140.004. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-385.729MRQ-504.303+118.573
MRQ-504.303TTM-140.004-364.299
TTM-140.004YOY7.476-147.480
TTM-140.0045Y-32.322-107.682
5Y-32.32210Y-34.888+2.566
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-385.729-2.259-383.470
MRQ-504.303-2.480-501.823
TTM-140.004-3.148-136.856
YOY7.476-3.244+10.720
5Y-32.322-5.991-26.331
10Y-34.888-6.692-28.196
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ardelyx Inc:

  • The EOD is 857.294. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 1,120.827. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 261.101. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD857.294MRQ1,120.827-263.533
MRQ1,120.827TTM261.101+859.726
TTM261.101YOY-4.790+265.891
TTM261.1015Y44.086+217.015
5Y44.08610Y5.680+38.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD857.294-2.995+860.289
MRQ1,120.827-3.289+1,124.116
TTM261.101-3.668+264.769
YOY-4.790-4.472-0.318
5Y44.086-8.001+52.087
10Y5.680-9.190+14.870
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Ardelyx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.31 means the investor is paying $10.31 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ardelyx Inc:

  • The EOD is 7.885. Based on the equity, the company is overpriced. -1
  • The MRQ is 10.309. Based on the equity, the company is expensive. -2
  • The TTM is 10.628. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD7.885MRQ10.309-2.424
MRQ10.309TTM10.628-0.319
TTM10.628YOY6.871+3.756
TTM10.6285Y8.271+2.357
5Y8.27110Y14.019-5.749
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.8852.001+5.884
MRQ10.3092.054+8.255
TTM10.6282.385+8.243
YOY6.8712.431+4.440
5Y8.2713.690+4.581
10Y14.0194.307+9.712
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ardelyx Inc.

4.8.1. Institutions holding Ardelyx Inc

Institutions are holding 61.441% of the shares of Ardelyx Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30HHG PLC9.08990.075921529880-4419443-17.0311
2024-06-30BlackRock Inc7.41070.0029175525604565222.6703
2024-09-30Vanguard Group Inc5.740.001713595548-60299-0.4416
2024-09-30State Street Corp5.12630.0034121418501767891.4775
2024-09-30Macquarie Group Ltd3.7780.06668948448204777329.675
2024-09-30Eventide Asset Management, LLC3.12980.8803741304974606711.1905
2024-09-30Geode Capital Management, LLC2.31690.00315487742172960.3162
2024-09-30Millennium Management LLC1.69380.0131401188080879025.2503
2024-09-30Morgan Stanley - Brokerage Accounts1.32340.00163134486-2957226-48.5451
2024-09-30Rubric Capital Management LP1.2920.34363060191124360668.4585
2024-09-30Goldman Sachs Group Inc1.00060.00262369852-551811-18.8869
2024-09-30Citadel Advisors Llc0.93260.002922089331948301747.5295
2024-09-30Nuveen Asset Management, LLC0.91490.0042216696138680.1788
2024-09-30Northern Trust Corp0.88680.00242100533254961.2287
2024-09-30Charles Schwab Investment Management Inc0.81860.00261938778407022.1444
2024-06-30Bank of America Corp0.7630.0012180710876419873.2755
2024-09-30Susquehanna International Group, LLP0.73530.0021174149152612143.289
2024-09-30Redmile Group, LLC0.70120.67411660763-220738-11.732
2024-06-30Deutsche Bank AG0.61290.004914516141167048.7425
2024-09-30Oracle Investment Management Inc0.57815.65341369200-118931-7.992
Total 48.84487.7426115690867+593785+0.5%

4.9.2. Funds holding Ardelyx Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Delaware Small Cap Core I3.08870.66217315608167946229.7981
2024-10-31Vanguard Total Stock Mkt Idx Inv2.97490.00247046229115030.1635
2024-11-27SPDR® S&P Biotech ETF2.75030.49946514226-197820-2.9472
2024-11-27iShares Russell 2000 ETF2.73130.04566469094-13510-0.2084
2024-09-30Janus Henderson Global Life Sciences1.93420.55194581284-427474-8.5345
2024-09-30Janus Henderson Global Life Sciences D1.93420.55374581284-59195-1.2756
2024-06-30Eventide Healthcare & Life Sciences I1.72592.10174087881-147119-3.4739
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.50390.01933562160-10143-0.2839
2024-10-31Janus Henderson Glb Life Scn I2 USD1.45290.4823441344418351.2306
2024-09-30Janus Global Life Science AUSD1.43530.54823399509-228280-6.2925
2024-06-30Eventide Gilead N1.08440.5674256854300
2024-09-30Janus Henderson Triton D1.07110.2617253689900
2024-09-30Janus Henderson US SMID Cap Growth1.07110.26222536899-1985607-43.905
2024-09-30Fidelity Small Cap Index0.99850.05942365079-15587-0.6547
2024-11-27iShares Russell 2000 Growth ETF0.88230.0889208985300
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.64930.02011537800-51000-3.21
2024-09-30Nuveen Quant Small Cap Equity R60.63480.2948150348000
2024-09-30Fidelity Extended Market Index0.57840.02261369891-40113-2.8449
2024-11-28Schwab US Small-Cap ETF™0.48450.03311475636480.0565
2024-10-31Vanguard Russell 2000 ETF0.44720.05071059305-6607-0.6198
Total 29.43327.127169713931-1449007-2.1%

5.3. Insider Transactions

Insiders are holding 1.694% of the shares of Ardelyx Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-25Michael RaabSELL250005.38
2024-11-20Michael RaabSELL319804.79
2024-11-20Laura A WilliamsSELL73664.79
2024-11-20Justin A RenzSELL52604.79
2024-11-11Michael RaabSELL27434.9
2024-11-06David P RosenbaumSELL271716.1
2024-11-04David P RosenbaumSELL271725.95
2024-10-28Michael RaabSELL250005.91
2024-10-11Michael RaabSELL75006.01
2024-09-27David P RosenbaumSELL495646.92
2024-09-26Michael RaabSELL30006.07
2024-09-13David P RosenbaumSELL53126.26
2024-09-11Michael RaabSELL350005.61
2024-08-27Michael RaabSELL75006.22
2024-08-20Justin A RenzSELL52895.86
2024-08-20David P RosenbaumSELL205076
2024-08-20Michael RaabSELL322255.86
2024-08-16David P RosenbaumSELL200005.94
2024-08-12Michael RaabSELL12295.71
2024-07-29Michael RaabSELL300005.64
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets367,863
Total Liabilities209,566
Total Stockholder Equity158,297
 As reported
Total Liabilities 209,566
Total Stockholder Equity+ 158,297
Total Assets = 367,863

Assets

Total Assets367,863
Total Current Assets284,098
Long-term Assets83,765
Total Current Assets
Cash And Cash Equivalents 47,429
Short-term Investments 142,973
Net Receivables 53,195
Inventory 11,378
Other Current Assets 29,123
Total Current Assets  (as reported)284,098
Total Current Assets  (calculated)284,098
+/-0
Long-term Assets
Property Plant Equipment 4,653
Long-term Assets Other 79,112
Long-term Assets  (as reported)83,765
Long-term Assets  (calculated)83,765
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities70,499
Long-term Liabilities139,067
Total Stockholder Equity158,297
Total Current Liabilities
Short-term Debt 5,134
Accounts payable 15,824
Other Current Liabilities 42,269
Total Current Liabilities  (as reported)70,499
Total Current Liabilities  (calculated)63,227
+/- 7,272
Long-term Liabilities
Long term Debt 100,707
Capital Lease Obligations 3,785
Long-term Liabilities  (as reported)139,067
Long-term Liabilities  (calculated)104,492
+/- 34,575
Total Stockholder Equity
Common Stock24
Retained Earnings -889,985
Accumulated Other Comprehensive Income 185
Other Stockholders Equity 1,048,073
Total Stockholder Equity (as reported)158,297
Total Stockholder Equity (calculated)158,297
+/-0
Other
Capital Stock24
Cash and Short Term Investments 190,402
Common Stock Shares Outstanding 235,911
Current Deferred Revenue7,272
Liabilities and Stockholders Equity 367,863
Net Debt 57,063
Net Invested Capital 259,004
Net Working Capital 213,599
Property Plant and Equipment Gross 4,653
Short Long Term Debt Total 104,492



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
37,884
0
0
0
42,904
40,548
123,478
117,729
113,414
105,399
148,188
138,066
116,946
180,498
155,379
241,317
213,131
187,765
164,122
143,105
157,903
142,837
228,536
206,668
183,332
166,135
137,980
119,410
259,782
235,322
217,343
198,555
201,562
210,293
204,982
170,848
149,913
129,408
131,610
144,672
190,066
217,019
211,203
289,379
297,579
342,382
343,488
367,863
367,863343,488342,382297,579289,379211,203217,019190,066144,672131,610129,408149,913170,848204,982210,293201,562198,555217,343235,322259,782119,410137,980166,135183,332206,668228,536142,837157,903143,105164,122187,765213,131241,317155,379180,498116,946138,066148,188105,399113,414117,729123,47840,54842,90400037,884
   > Total Current Assets 
0
0
0
0
41,836
39,115
122,147
116,373
111,283
101,906
143,923
133,471
112,235
175,697
150,404
234,200
203,992
178,008
153,945
133,630
149,871
135,320
221,688
199,322
177,721
154,312
127,241
110,834
252,376
228,582
211,626
193,793
195,238
205,376
186,492
153,379
134,799
114,225
114,107
119,875
154,484
167,047
162,118
241,216
246,111
257,939
263,020
284,098
284,098263,020257,939246,111241,216162,118167,047154,484119,875114,107114,225134,799153,379186,492205,376195,238193,793211,626228,582252,376110,834127,241154,312177,721199,322221,688135,320149,871133,630153,945178,008203,992234,200150,404175,697112,235133,471143,923101,906111,283116,373122,14739,11541,8360000
       Cash And Cash Equivalents 
32,903
0
0
0
34,435
33,221
117,814
112,044
107,286
98,318
141,534
129,047
107,004
171,678
146,669
160,360
74,598
71,213
63,636
59,454
75,383
67,745
91,751
75,015
78,768
92,036
89,626
92,673
181,133
105,895
100,494
91,009
91,032
84,070
86,745
75,288
72,428
47,077
53,408
61,628
96,140
92,487
30,058
33,767
21,470
36,147
41,890
47,429
47,42941,89036,14721,47033,76730,05892,48796,14061,62853,40847,07772,42875,28886,74584,07091,03291,009100,494105,895181,13392,67389,62692,03678,76875,01591,75167,74575,38359,45463,63671,21374,598160,360146,669171,678107,004129,047141,53498,318107,286112,044117,81433,22134,43500032,903
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
69,726
126,225
102,210
85,088
69,834
58,593
59,704
120,980
111,391
89,321
59,524
34,315
10,870
66,379
117,312
104,347
94,488
95,452
94,142
85,064
66,363
44,261
42,627
27,604
28,995
27,769
37,886
97,521
131,313
162,829
166,431
144,071
142,973
142,973144,071166,431162,829131,31397,52137,88627,76928,99527,60442,62744,26166,36385,06494,14295,45294,488104,347117,31266,37910,87034,31559,52489,321111,391120,98059,70458,59369,83485,088102,210126,22569,726000000000000000
       Net Receivables 
0
0
0
0
6,436
4,977
3,025
2,660
2,584
2,043
27
0
0
0
0
0
0
0
0
0
10,796
5,000
5,030
5,167
5,085
7
17
2,699
750
750
750
750
0
5,783
0
287
502
4,394
5,623
5,208
7,733
12,120
9,109
43,263
22,031
28,162
37,241
53,195
53,19537,24128,16222,03143,2639,10912,1207,7335,2085,6234,39450228705,78307507507507502,6991775,0855,1675,0305,00010,796000000000272,0432,5842,6603,0254,9776,4360000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,487
4,529
1,250
3,282
4,823
7,617
8,524
12,448
9,813
13,756
11,378
11,37813,7569,81312,4488,5247,6174,8233,2821,2504,5293,4870000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
1,068
1,433
1,331
1,356
2,131
3,493
4,265
4,595
4,711
4,801
4,975
7,117
9,139
9,757
10,177
9,475
8,032
7,517
6,848
7,346
5,611
11,823
10,739
8,576
7,406
6,740
5,717
4,762
6,324
4,917
18,490
17,469
15,114
15,183
17,503
24,797
35,582
49,972
49,085
48,163
51,468
84,443
80,468
83,765
83,76580,46884,44351,46848,16349,08549,97235,58224,79717,50315,18315,11417,46918,4904,9176,3244,7625,7176,7407,4068,57610,73911,8235,6117,3466,8487,5178,0329,47510,1779,7579,1397,1174,9754,8014,7114,5954,2653,4932,1311,3561,3311,4331,0680000
       Property Plant Equipment 
844
0
0
0
530
551
1,138
1,152
2,131
3,289
4,061
4,391
4,711
4,597
4,827
6,969
8,991
8,915
9,335
8,622
8,032
7,358
6,689
5,996
5,611
10,473
9,388
8,396
7,406
6,436
5,446
4,513
4,210
3,959
17,185
16,231
15,114
13,955
12,595
11,476
10,518
9,074
8,117
7,639
6,598
5,660
5,340
4,653
4,6535,3405,6606,5987,6398,1179,07410,51811,47612,59513,95515,11416,23117,1853,9594,2104,5135,4466,4367,4068,3969,38810,4735,6115,9966,6897,3588,0328,6229,3358,9158,9916,9694,8274,5974,7114,3914,0613,2892,1311,1521,138551530000844
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,114
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,11400000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
538
882
193
204
204
204
204
204
204
204
148
148
148
842
842
853
159
159
159
1,350
1,350
1,350
1,351
180
314
304
271
249
552
958
1,305
1,238
1,150
1,228
4,908
13,321
25,064
40,898
40,968
40,524
44,870
78,783
75,128
79,112
79,11275,12878,78344,87040,52440,96840,89825,06413,3214,9081,2281,1501,2381,3059585522492713043141801,3511,3501,3501,3501591591598538428421481481482042042042042042042041938825380000
> Total Liabilities 
39,121
0
0
0
50,228
41,792
60,611
54,428
52,732
47,399
5,928
12,936
8,045
12,750
14,774
18,424
19,980
20,081
19,144
16,468
18,591
13,861
65,122
65,220
67,519
74,294
69,363
70,252
73,127
67,565
70,993
67,215
75,450
79,482
87,413
89,416
67,296
65,218
78,568
77,811
91,737
91,598
88,042
98,218
130,763
191,491
196,498
209,566
209,566196,498191,491130,76398,21888,04291,59891,73777,81178,56865,21867,29689,41687,41379,48275,45067,21570,99367,56573,12770,25269,36374,29467,51965,22065,12213,86118,59116,46819,14420,08119,98018,42414,77412,7508,04512,9365,92847,39952,73254,42860,61141,79250,22800039,121
   > Total Current Liabilities 
16,791
0
0
0
17,139
18,768
27,334
19,397
5,557
19,912
5,546
12,584
7,723
12,458
14,061
17,635
19,201
19,314
18,388
15,727
17,871
13,162
15,609
15,549
17,728
20,826
16,333
17,679
22,220
23,417
33,650
16,534
28,416
41,790
57,785
68,768
57,548
47,843
48,699
51,951
74,628
63,063
61,689
43,529
50,393
56,895
62,436
70,499
70,49962,43656,89550,39343,52961,68963,06374,62851,95148,69947,84357,54868,76857,78541,79028,41616,53433,65023,41722,22017,67916,33320,82617,72815,54915,60913,16217,87115,72718,38819,31419,20117,63514,06112,4587,72312,5845,54619,9125,55719,39727,33418,76817,13900016,791
       Short-term Debt 
0
0
0
0
0
0
0
0
15,979
0
0
0
0
0
0
0
0
0
0
0
0
0
10,891
11,678
585
2,102
2,318
2,504
3,791
10,152
16,542
2,770
6,284
18,079
39,295
47,835
35,756
29,731
30,064
30,332
30,605
30,878
31,157
4,321
4,435
4,314
7,100
5,134
5,1347,1004,3144,4354,32131,15730,87830,60530,33230,06429,73135,75647,83539,29518,0796,2842,77016,54210,1523,7912,5042,3182,10258511,67810,891000000000000015,97900000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,836
0
0
2,102
0
0
1,183
7,437
13,716
0
4,167
16,667
36,111
44,444
32,264
26,139
26,373
26,541
26,711
26,880
27,052
0
0
0
0
0
0000027,05226,88026,71126,54126,37326,13932,26444,44436,11116,6674,167013,7167,4371,183002,1020048,8360000000000000000000000
       Accounts payable 
1,146
0
0
0
2,284
2,530
2,308
1,022
3,129
2,544
2,684
2,714
2,777
4,875
4,746
6,298
5,635
5,893
4,713
1,723
17,871
1,761
3,172
2,269
16,728
2,925
1,260
2,689
2,187
1,012
4,212
2,490
5,626
5,378
2,587
4,263
4,277
5,030
4,294
3,113
10,859
10,513
5,294
7,736
11,138
17,277
10,881
15,824
15,82410,88117,27711,1387,7365,29410,51310,8593,1134,2945,0304,2774,2632,5875,3785,6262,4904,2121,0122,1872,6891,2602,92516,7282,2693,1721,76117,8711,7234,7135,8935,6356,2984,7464,8752,7772,7142,6842,5443,1291,0222,3082,5302,2840001,146
       Other Current Liabilities 
15,645
0
0
0
1,027
1,263
1,805
1,895
2,428
1,415
2,862
9,870
4,946
7,583
9,315
11,337
13,566
13,421
13,675
14,004
13,938
10,401
546
602
585
570
594
779
11,701
8,887
10,655
10,389
12,329
15,610
14,491
16,143
12,788
4,519
1,920
14,503
19,928
16,127
19,279
27,400
27,638
28,718
33,626
42,269
42,26933,62628,71827,63827,40019,27916,12719,92814,5031,9204,51912,78816,14314,49115,61012,32910,38910,6558,88711,70177959457058560254610,40113,93814,00413,67513,42113,56611,3379,3157,5834,9469,8702,8621,4152,4281,8951,8051,2631,02700015,645
   > Long-term Liabilities 
0
0
0
0
33,089
23,024
33,277
35,031
47,175
27,487
382
352
322
292
713
789
779
767
756
741
720
699
49,513
49,671
49,791
53,468
53,030
52,573
50,907
44,148
37,343
50,681
47,034
37,692
29,628
20,648
9,748
17,375
29,869
25,860
17,109
28,535
26,353
54,689
80,370
134,596
134,062
139,067
139,067134,062134,59680,37054,68926,35328,53517,10925,86029,86917,3759,74820,64829,62837,69247,03450,68137,34344,14850,90752,57353,03053,46849,79149,67149,51369972074175676777978971329232235238227,48747,17535,03133,27723,02433,0890000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,836
49,020
49,209
49,399
49,597
49,803
48,831
42,793
36,735
50,681
46,621
34,348
15,133
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000015,13334,34846,62150,68136,73542,79348,83149,80349,59749,39949,20949,02048,8360000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
-15,979
0
0
0
0
0
0
0
0
0
0
0
0
0
-10,891
-11,678
-585
4,069
3,433
2,770
893
-6,082
-13,108
0
-3,754
-16,270
-24,563
-33,775
-22,516
-17,327
-18,516
-19,663
-20,856
-22,066
-23,300
2,887
1,725
778
-2,454
-1,349
-1,349-2,4547781,7252,887-23,300-22,066-20,856-19,663-18,516-17,327-22,516-33,775-24,563-16,270-3,7540-13,108-6,0828932,7703,4334,069-585-11,678-10,8910000000000000-15,97900000000
       Long-term Liabilities Other 
0
0
0
0
0
0
107
72
122
297
382
352
322
292
713
789
779
767
756
741
0
699
677
651
0
4,069
3,433
2,770
2,076
1,355
608
0
413
3,344
14,495
0
14,475
17,375
0
25,860
17,109
28,535
26,353
170
0
0
0
0
000017026,35328,53517,10925,860017,37514,475014,4953,34441306081,3552,0762,7703,4334,0690651677699074175676777978971329232235238229712272107000000
       Deferred Long Term Liability 
0
0
0
0
0
0
33,170
34,959
31,074
27,190
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000027,19031,07434,95933,170000000
> Total Stockholder Equity
0
0
0
0
-7,324
-1,244
62,867
63,301
60,682
58,000
142,260
125,130
108,901
167,748
140,605
222,893
193,151
167,684
144,978
126,637
139,312
128,976
163,414
141,448
115,813
91,841
68,617
49,158
186,655
167,757
146,350
131,340
126,112
130,811
117,569
81,432
82,617
64,190
53,042
66,861
98,329
125,421
123,161
191,161
166,816
150,891
146,990
158,297
158,297146,990150,891166,816191,161123,161125,42198,32966,86153,04264,19082,61781,432117,569130,811126,112131,340146,350167,757186,65549,15868,61791,841115,813141,448163,414128,976139,312126,637144,978167,684193,151222,893140,605167,748108,901125,130142,26058,00060,68263,30162,867-1,244-7,3240000
   Common Stock
0
0
0
0
0
1
2
2
2
3
3
3
3
4
4
5
5
5
5
5
5
5
6
6
6
6
6
6
9
9
9
9
9
10
10
11
13
14
15
19
20
21
22
23
23
23
23
24
242323232322212019151413111010999996666665555555443333222100000
   Retained Earnings Total Equity00000-824,031-806,910-780,137-790,832-767,939-741,001-712,9300-633,109-587,920-554,765-525,889-507,781-482,825-460,452-440,662-417,123-391,656-365,512-337,650-313,524-291,232-278,214-288,328-267,604-241,883-213,875-182,601-153,570-124,955-101,488-84,488-66,362-75,369-71,867-67,896-67,971000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-3,332
0
-123,478
-117,729
-3,634
-3,634
0
0
-3,808
-3,808
0
-25
-71
-48
-40
-10
-47
-91
-36
-17
-38
12
16
4
20
-44
317
90
-4
-7
4
3
-6
-88
-109
-114
-54
-20
-210
-201
224
-20
-101
185
185-101-20224-201-210-20-54-114-109-88-634-7-490317-442041612-38-17-36-91-47-10-40-48-71-250-3,808-3,80800-3,634-3,634-117,729-123,4780-3,3320000
   Capital Surplus 
0
0
0
0
0
0
130,836
131,195
132,547
133,366
208,619
209,615
210,386
292,699
294,171
405,514
407,092
409,610
412,617
414,970
417,568
420,294
476,968
479,109
481,357
483,479
485,718
489,810
647,078
650,617
653,805
657,130
680,872
718,728
750,664
0
795,540
805,265
821,075
857,788
878,500
932,330
947,380
0
0
0
0
0
00000947,380932,330878,500857,788821,075805,265795,5400750,664718,728680,872657,130653,805650,617647,078489,810485,718483,479481,357479,109476,968420,294417,568414,970412,617409,610407,092405,514294,171292,699210,386209,615208,619133,366132,547131,195130,836000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
8,506
70,479
130,836
131,195
136,181
133,366
208,619
209,615
214,194
292,699
294,171
405,514
407,092
409,610
412,617
414,970
417,568
420,294
476,968
479,109
481,357
483,479
485,718
489,810
647,078
650,617
653,805
657,130
680,872
718,728
750,664
758,114
795,540
805,265
821,075
857,788
878,500
932,330
947,380
1,008,741
1,012,773
1,023,610
1,036,244
1,048,073
1,048,0731,036,2441,023,6101,012,7731,008,741947,380932,330878,500857,788821,075805,265795,540758,114750,664718,728680,872657,130653,805650,617647,078489,810485,718483,479481,357479,109476,968420,294417,568414,970412,617409,610407,092405,514294,171292,699214,194209,615208,619133,366136,181131,195130,83670,4798,5060000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.